MOORESTOWN, N.J., April 23, 2018– Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ:TRHC), a healthcare technology company optimizing medication safety, announced today that subsidiary SinfoníaRx has published its 2018 Program Performance Report, presenting a comprehensive analysis of calendar-year 2017.
“Our Annual Program Performance Report not only serves as an opportunity to reflect on our achievements throughout 2017, but also presents a platform to highlight the capabilities of our innovative healthcare solutions,” says SinfoníaRx CEO, Kevin Boesen, PharmD. “We’re better positioned than ever to continue to provide best-in-class Medication Therapy Management services to our clients and patients across the nation.”
A critical organizational change took place in 2017 when SinfoniaRx joined medication therapy management company Tabula Rasa HealthCare. Other highlights in the 2017 Performance Report include an increase to 3.3 million interventions completed in 2017 vs. 1.1 million in 2016; 307,000 comprehensive medication reviews vs. 253,000 in 2016. The complete SinfoníaRx Program Performance Report can be found on the company’s website by clicking here.
The publishing of the Program Performance Report comes as SinfoníaRx celebrates the establishment of its latest clinical call center in Austin, Texas, in partnership with the University of Texas at Austin College of Pharmacy. SinfoníaRx supports a CPPA (Center for Pharmacy Practice Accreditation) accredited model with five national call centers and is contracted with a number of the top colleges of pharmacy in the nation.
About Tabula Rasa Healthcare
Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, visit: www.TRHC.com.
SinfoníaRx, a Tabula Rasa HealthCare Company, is a leading provider of Medication Therapy Management (MTM) services. Through a comprehensive suite of innovative healthcare solutions, SinfoníaRx provides direct support to health plans, health systems, provider organizations, and pharmacies. SinfoníaRx’s staff of nationally renowned clinical pharmacists, pharmacy interns, pharmacy technicians and interprofessional team work directly with caregivers, patients, and providers to ensure the most effective and safest medication therapy possible. For more information, visit: www.SinfoníaRx.com.
This press release includes forward-looking statements that we believe to be reasonable as of today’s date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 14, 2018, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website http://ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.
Bob East or Asher Dewhurst